An antibody-like peptide that recognizes malignancy among thyroid nodules

Area of Science:

• Biomarker discovery
• Proteomics
• Thyroid cancer diagnostics

Background:

• Urgent need for reliable biomarkers to differentiate malignant from indeterminate thyroid nodules.
• Current diagnostic methods for follicular lesions have limitations in distinguishing benign from malignant types.

Purpose of the Study:

• To identify novel biomarkers for distinguishing malignant thyroid nodules from indeterminate follicular lesions.
• To evaluate the diagnostic potential of a newly identified antibody-like peptide, CaT12.

Main Methods:

• Utilized a subtractive proteomic strategy with a phage-displayed peptide library and Biopanning and Rapid Analysis of Selective Interactive Ligands (BRASIL) method.
• Selected and validated antibody-like peptide CaT12 using phage-ELISA and immunohistochemistry on tissue microarrays (TMAs) of diverse thyroid tissues.
• Assessed CaT12's performance in identifying papillary thyroid carcinoma (PTC) and differentiating follicular variant PTC (FVPTC) from other follicular lesions.

Main Results:

• CaT12 demonstrated high sensitivity (91.2%) and specificity (85.1%) in identifying PTC among thyroid nodular lesions.
• CaT12 accurately distinguished FVPTC from follicular adenoma (FA) with 91.9% accuracy and from nodular goiter (NG) with 83.1% accuracy.
• CaT12 showed significant accuracy in differentiating FVPTC from follicular carcinoma (FC) with 88.7% accuracy.

Conclusions:

• The subtractive proteomic strategy effectively identified CaT12, a promising antibody-like biomarker for thyroid nodule malignancy.
• CaT12 aids in distinguishing malignant thyroid nodules and characterizing follicular lesions, potentially improving diagnostic accuracy.
• This novel biomarker offers a valuable tool for improving the diagnosis and management of thyroid nodules.